Thrombocythemia, Essential
"Thrombocythemia, Essential" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
| Descriptor ID |
D013920
|
| MeSH Number(s) |
C15.378.100.832 C15.378.140.860.800 C15.378.190.636.860.800 C15.378.463.825
|
| Concept/Terms |
Thrombocythemia, Essential- Thrombocythemia, Essential
- Essential Thrombocythemia
- Essential Thrombocythemias
- Thrombocythemias, Essential
- Thrombocythemia, Hemorrhagic
- Primary Thrombocythemia
- Thrombocythemia, Primary
- Primary Thrombocythemias
- Thrombocythemias, Primary
- Thrombocytosis, Primary
- Primary Thrombocytoses
- Primary Thrombocytosis
- Thrombocytoses, Primary
- Hemorrhagic Thrombocythemia
- Hemorrhagic Thrombocythemias
- Thrombocythemias, Hemorrhagic
- Thrombocythemia, Idiopathic
- Idiopathic Thrombocythemia
- Idiopathic Thrombocythemias
- Thrombocythemias, Idiopathic
Thrombocytosis, Autosomal Dominant- Thrombocytosis, Autosomal Dominant
- Autosomal Dominant Thrombocytoses
- Autosomal Dominant Thrombocytosis
- Dominant Thrombocytoses, Autosomal
- Dominant Thrombocytosis, Autosomal
- Thrombocytoses, Autosomal Dominant
|
Below are MeSH descriptors whose meaning is more general than "Thrombocythemia, Essential".
Below are MeSH descriptors whose meaning is more specific than "Thrombocythemia, Essential".
This graph shows the total number of publications written about "Thrombocythemia, Essential" by people in this website by year, and whether "Thrombocythemia, Essential" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombocythemia, Essential" by people in Profiles.
-
Gross-Davis CA, Heavner K, Frank AL, Newschaffer C, Klotz J, Santella RM, Burstyn I. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. Int J Environ Res Public Health. 2015 Feb 24; 12(3):2465-85.
-
Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54.
-
Selvan SR, Sheehy PF, Heinemann FS, Anbuganapathi S. Bone marrow failure due to T-cell large granular lymphocytic leukemia in a patient with essential thrombocythemia. Leuk Res. 2011 Feb; 35(2):278-82.
-
Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008 Nov; 22(11):2020-8.
-
Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008 Mar; 93(3):331-5.
-
Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost. 2006 Apr; 32(3):251-9.
-
Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006; 19(3):617-33.
-
Landolfi R, Patrono C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Leuk Lymphoma. 1996 Sep; 22 Suppl 1:83-6.
-
Schick BP, Eras JL, Mintz PS. Phosphorothioate oligonucleotides cause degradation of secretory but not intracellular serglycin proteoglycan core protein in a sequence-independent manner in human megakaryocytic tumor cells. Antisense Res Dev. 1995; 5(1):59-65.
-
Pui CH, Rivera G, Mirro J, Stass S, Peiper S, Murphy SB. Acute megakaryoblastic leukemia. Blast cell aggregates simulating metastatic tumor. Arch Pathol Lab Med. 1985 Nov; 109(11):1033-5.